SCHEMBL4903790

SCHEMBL4903790

Cc1ccc(S(=O)(=O)NCCc2ccc3oc(-c4ccccc4)nc3c2)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.52
PTPN5 P54829 12/20 0.52
PTPN1 P18031 12/20 0.52
PTPN2 P17706 11/20 0.52
HSPD1 P10809 3/20 0.47
HSPE1 P61604 3/20 0.47
MAPT P10636 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
S1PR1 P21453 1/20 0.45
S1PR3 Q99500 1/20 0.45
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4905165 0.94 PTPN5 (0.52) LMNAPTPN5PTPN1PTPN2HSPD1
SCHEMBL4904651 0.90 PTPN5 (0.55) PTPN5PTPN1PTPN2HSPD1HSPE1
SCHEMBL4909037 0.90 PTPN5 (0.48) PTPN5PTPN1PTPN2HSPD1HSPE1
SCHEMBL4895939 0.89 PTPN5 (0.50) LMNAPTPN5PTPN1PTPN2HSPD1
SCHEMBL4912003 0.85 PTPN1 (0.48) PTPN5PTPN1PTPN2HSPD1HSPE1
SCHEMBL4906124 0.85 PTPN5 (0.50) PTPN5PTPN1PTPN2HSPD1HSPE1
SCHEMBL4897733 0.85 PTPN5 (0.54) PTPN5PTPN1PTPN2HSPD1HSPE1
SCHEMBL4904425 0.83 LMNA (0.52) LMNAPTPN5PTPN1PTPN2MAPT
SCHEMBL4904168 0.82 LMNA (0.56) LMNAKDM4EALDH1A1HPGDPOLB
SCHEMBL4902822 0.81 LMNA (0.52) LMNAMAPTKDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD LMNA 317/4885PTPN5 1700/4885PTPN1 1702/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885PTPN5 2304/4885PTPN1 2340/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885PTPN5 2304/4885PTPN1 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.